Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.40 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.37 |
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.37 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28540842 | 0.86 | CYP19A1 (0.52) | KMT2AHTTGAACA2CA5A | |
| SCHEMBL11221351 | 0.86 | HTT (0.48) | KMT2AHTTGAACA2CA5A | |
| Lithium Ion SCHEMBL28617436 | 0.82 | CYP19A1 (0.52) | KMT2AHTTGAACA2CA5A | |
| SCHEMBL2820707 | 0.81 | ACP1 (0.43) | ACP1KMT2AHTTGAACA2 | |
| SCHEMBL2880510 | 0.81 | ACP1 (0.43) | ACP1KMT2AHTTGAACA2 | |
| SCHEMBL11685973 | 0.81 | CA2 (0.56) | ACP1KMT2AHTTGAACA2 | |
| SCHEMBL1024318 | 0.81 | ACP1 (0.50) | ACP1KMT2AHTTGAACA2 | |
| SCHEMBL2820721 | 0.80 | ACP1 (0.49) | ACP1KMT2AHTTGAACA2 | |
| SCHEMBL11078667 | 0.80 | DUSP5 (0.45) | ACP1CA2CA5ACA1CA12 | |
| SCHEMBL31259725 | 0.77 | CA2 (0.59) | ACP1KMT2AHTTGAACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242118-B2 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| EP-1849469-B1 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2010-08-12 | — | — | US | disclosed |
| US-7700586-B2 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1461038-B9 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS INC (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-1849469-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | Actimis Pharmaceuticals, Inc., (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1461038-B1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20050070582-A1 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | BAYER HEALTHCARE AG (DE) | 2005-03-31 | — | — | US | disclosed |
| EP-1461038-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | Bayer HealthCare AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003022277-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | CCR3, CCR1, CCR2 | CA2 895/4885CA1 2755/4885CA12 2091/4885 |
| US-20050070582-A1 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | CCR3, CCR1, CCR2 | CA2 895/4885CA1 2755/4885CA12 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.